The discrepancy in the prognostic values of PD-L1 may be because the neoadjuvant or adjuvant treatment agents may serve as confounders for the PD-1/PD-L1 axis and because the PD-L1 expression protects tumor cells from pro-apoptotic agents [10]. This evidence concerns the gene CD274 and neoplasm.